Compare Novavax Inc (NVAX) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Novavax Inc trades at $12.7 (market cap $1.82B), while Vanguard International High Dividend Yield ETF trades at $101.05 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 12.5× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Vanguard International High Dividend Yield ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| NVAX | VYMI | |
|---|---|---|
Market Cap | $1.82B | $22.80B |
Volume | 6,198,505 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $12.56 | $107.13 |
52-Week Low | $6.22 | $82.92 |
Typical Hold Time | 59 Days | 50 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
VYMI trades at $100.66, up 0.43% on the day, with a bearish technical signal from moving averages but neutral oscillators. The ETF focuses on international high dividend yield stocks, with recent institutional buying activity from Envestnet and Corient Private Wealth. Recent news highlights strong performance with a 29% one-year return and 14.13% five-year average annual return, supported by financials, energy, and healthcare sector exposure.
The outlook remains positive given Vanguard's bullish stance on international developed markets and the ETF's attractive dividend yield. Key risks include global economic volatility and currency fluctuations, but institutional accumulation and sector alignment with rising rates support the investment thesis for income-focused investors seeking international diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
